SCHEMBL10276044

SCHEMBL10276044

N#Cc1ccc(-c2ccc3c(=O)n4nc(-c5ccccc5)c(-c5ccc(F)cc5F)c4[nH]c3c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAT P00750 1/20 0.40
ADORA1 P30542 2/20 0.38
ADORA2A P29274 1/20 0.38
ARF6 P62330 3/20 0.38
FLT3 P36888 4/20 0.38
FEN1 P39748 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALOX5 P09917 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
IDO1 P14902 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
DHODH Q02127 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275539 0.87 FLT3 (0.39) ARF6FLT3KMT2A
SCHEMBL10276150 0.86 KDM4E (0.42) PLATARF6FEN1MEN1KMT2A
SCHEMBL10276262 0.86 ARF6 (0.49) PLATARF6FLT3
SCHEMBL10275869 0.85 FLT3 (0.38) ARF6FLT3GABRG2GABRB3GABRA5
SCHEMBL10275923 0.84 ARF6 (0.46) PLATARF6FLT3
SCHEMBL10275641 0.84 PLAT (0.40) PLATADORA1ADORA2AARF6MEN1
SCHEMBL10275610 0.83 PLAT (0.42) PLATADORA1ADORA2AARF6MEN1
SCHEMBL10275650 0.80 FLT3 (0.38) FLT3ALOX5GABRG2GABRB3GABRA5
SCHEMBL10275336 0.79 ALDH1A1 (0.45) PLATMEN1KMT2AKDM4EALDH1A1
SCHEMBL10313602 0.79 FEN1 (0.46) PLATARF6FLT3FEN1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed
WO-2011035518-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF 辽宁利锋科技开发有限公司 (CN) 2011-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 PLAT 2180/4885ADORA1 11/4885ADORA2A 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.